Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials,Signal Transduction and Targeted Therapy

当前位置： X-MOL 学术 › Signal Transduct. Target Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials
Signal Transduction and Targeted Therapy ( IF 40.8 ) Pub Date : 2017-10-09 , DOI: 10.1038/sigtrans.2017.54
Wen-ying Zhang , Yang Liu , Yao Wang , Chun-meng Wang , Qing-ming Yang , Hong-li Zhu , Wei-dong Han

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials, Published online: 09 October 2017; doi:10.1038/sigtrans.2017.54

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials

中文翻译：